Does the media favor IDYA or AMPH?

In the previous week, IDEAYA Biosciences had 2 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 4 mentions for IDEAYA Biosciences and 2 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 0.85 beat IDEAYA Biosciences' score of 0.48 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amphastar Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMPH or BEAM?

In the previous week, Beam Therapeutics had 1 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 3 mentions for Beam Therapeutics and 2 mentions for Amphastar Pharmaceuticals. Beam Therapeutics' average media sentiment score of 1.20 beat Amphastar Pharmaceuticals' score of 0.85 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ELVN or AMPH?

In the previous week, Enliven Therapeutics had 2 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 4 mentions for Enliven Therapeutics and 2 mentions for Amphastar Pharmaceuticals. Enliven Therapeutics' average media sentiment score of 0.91 beat Amphastar Pharmaceuticals' score of 0.85 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amphastar Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Amphastar Pharmaceuticals (AMPH) Competitors

$19.75 -0.11 (-0.55%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$20.32 +0.57 (+2.91%)

As of 07/17/2026 07:06 PM Eastern

Compare

AMPH vs. GMTX, IDYA, BEAM, RARE, and ELVN

Should you buy Amphastar Pharmaceuticals stock or one of its competitors? MarketBeat compares Amphastar Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amphastar Pharmaceuticals include Gemini Therapeutics (GMTX), IDEAYA Biosciences (IDYA), Beam Therapeutics (BEAM), Ultragenyx Pharmaceutical (RARE), and Enliven Therapeutics (ELVN). These companies are all part of the "pharmaceutical products" industry.

How does Amphastar Pharmaceuticals compare to Gemini Therapeutics?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Amphastar Pharmaceuticals has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.21	$98.09M	$1.66	11.90
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Amphastar Pharmaceuticals has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market.

Amphastar Pharmaceuticals presently has a consensus price target of $22.00, indicating a potential upside of 11.39%. Given Amphastar Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Amphastar Pharmaceuticals is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	3 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.63
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Gemini Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Gemini Therapeutics	N/A	-38.78%	-35.88%

In the previous week, Amphastar Pharmaceuticals had 2 more articles in the media than Gemini Therapeutics. MarketBeat recorded 2 mentions for Amphastar Pharmaceuticals and 0 mentions for Gemini Therapeutics. Amphastar Pharmaceuticals' average media sentiment score of 0.85 beat Gemini Therapeutics' score of 0.00 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Amphastar Pharmaceuticals	Positive
Gemini Therapeutics	Neutral

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Amphastar Pharmaceuticals beats Gemini Therapeutics on 13 of the 14 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

IDEAYA Biosciences presently has a consensus target price of $50.25, suggesting a potential upside of 39.54%. Amphastar Pharmaceuticals has a consensus target price of $22.00, suggesting a potential upside of 11.39%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe IDEAYA Biosciences is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
Amphastar Pharmaceuticals	3 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.63

Amphastar Pharmaceuticals has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	14.47	-$113.70M	-$1.60	N/A
Amphastar Pharmaceuticals	$719.89M	1.21	$98.09M	$1.66	11.90

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to IDEAYA Biosciences' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%

IDEAYA Biosciences has a beta of -0.09, meaning that its stock price is 109% less volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

In the previous week, IDEAYA Biosciences had 2 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 4 mentions for IDEAYA Biosciences and 2 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 0.85 beat IDEAYA Biosciences' score of 0.48 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amphastar Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amphastar Pharmaceuticals beats IDEAYA Biosciences on 10 of the 16 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Beam Therapeutics?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Amphastar Pharmaceuticals has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the broader market.

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Beam Therapeutics' net margin of -39.66%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Amphastar Pharmaceuticals currently has a consensus target price of $22.00, suggesting a potential upside of 11.39%. Beam Therapeutics has a consensus target price of $46.85, suggesting a potential upside of 70.16%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Beam Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	3 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.63
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Amphastar Pharmaceuticals has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.21	$98.09M	$1.66	11.90
Beam Therapeutics	$164.01M	17.27	-$79.99M	-$0.68	N/A

In the previous week, Beam Therapeutics had 1 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 3 mentions for Beam Therapeutics and 2 mentions for Amphastar Pharmaceuticals. Beam Therapeutics' average media sentiment score of 1.20 beat Amphastar Pharmaceuticals' score of 0.85 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Beam Therapeutics beats Amphastar Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Ultragenyx Pharmaceutical?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Amphastar Pharmaceuticals has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

Amphastar Pharmaceuticals has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.21	$98.09M	$1.66	11.90
Ultragenyx Pharmaceutical	$673M	4.28	-$575M	-$6.11	N/A

Amphastar Pharmaceuticals currently has a consensus price target of $22.00, suggesting a potential upside of 11.39%. Ultragenyx Pharmaceutical has a consensus price target of $58.41, suggesting a potential upside of 99.49%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	3 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.63
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

In the previous week, Ultragenyx Pharmaceutical had 2 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 4 mentions for Ultragenyx Pharmaceutical and 2 mentions for Amphastar Pharmaceuticals. Ultragenyx Pharmaceutical's average media sentiment score of 0.91 beat Amphastar Pharmaceuticals' score of 0.85 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Amphastar Pharmaceuticals beats Ultragenyx Pharmaceutical on 9 of the 17 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Enliven Therapeutics currently has a consensus price target of $69.17, indicating a potential upside of 30.01%. Amphastar Pharmaceuticals has a consensus price target of $22.00, indicating a potential upside of 11.39%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Enliven Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Amphastar Pharmaceuticals	3 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.63

Enliven Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Amphastar Pharmaceuticals has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Amphastar Pharmaceuticals	$719.89M	1.21	$98.09M	$1.66	11.90

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Enliven Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%

In the previous week, Enliven Therapeutics had 2 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 4 mentions for Enliven Therapeutics and 2 mentions for Amphastar Pharmaceuticals. Enliven Therapeutics' average media sentiment score of 0.91 beat Amphastar Pharmaceuticals' score of 0.85 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amphastar Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amphastar Pharmaceuticals beats Enliven Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Amphastar Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMPH vs. The Competition

Export

Metric	Amphastar Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$870.62M	$6.40B	$6.86B	$12.28B
Dividend Yield	N/A	0.69%	2.67%	9.34%
P/E Ratio	11.90	9.62	27.25	23.92
Price / Sales	1.21	27.91	517.83	88.82
Price / Cash	4.64	8.30	52.99	60.41
Price / Book	1.15	4.43	10.69	6.18
Net Income	$98.09M	$99.67M	$3.59B	$332.29M
7 Day Performance	5.50%	0.77%	-2.20%	-2.05%
1 Month Performance	5.00%	8.98%	1.63%	-2.18%
1 Year Performance	-4.22%	133.42%	25.64%	17.67%

Amphastar Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMPH Amphastar Pharmaceuticals	3.2015 of 5 stars	$19.75 -0.6%	$22.00 +11.4%	-4.2%	$870.62M	$719.89M	11.90	1,976	News Coverage
GMTX Gemini Therapeutics	N/A	$75.98 -0.8%	N/A	+31.8%	$3.29B	N/A	N/A	30	High Trading Volume
IDYA IDEAYA Biosciences	3.3017 of 5 stars	$36.65 +1.4%	$50.25 +37.1%	+66.8%	$3.22B	$218.71M	N/A	80	News Coverage Gap Down
BEAM Beam Therapeutics	3.5113 of 5 stars	$30.89 -0.4%	$46.85 +51.7%	+32.7%	$3.18B	$139.74M	N/A	510	Positive News Gap Down
RARE Ultragenyx Pharmaceutical	3.5846 of 5 stars	$32.03 -3.6%	$58.41 +82.4%	+11.3%	$3.15B	$673M	N/A	1,371	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMPH) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amphastar Pharmaceuticals (AMPH) Competitors

AMPH vs. GMTX, IDYA, BEAM, RARE, and ELVN

How does Amphastar Pharmaceuticals compare to Gemini Therapeutics?

Summary

How does Amphastar Pharmaceuticals compare to IDEAYA Biosciences?

Summary

How does Amphastar Pharmaceuticals compare to Beam Therapeutics?

Summary

How does Amphastar Pharmaceuticals compare to Ultragenyx Pharmaceutical?

Summary

How does Amphastar Pharmaceuticals compare to Enliven Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH vs. The Competition

Amphastar Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amphastar Pharmaceuticals (AMPH) Competitors

AMPH vs. GMTX, IDYA, BEAM, RARE, and ELVN

How does Amphastar Pharmaceuticals compare to Gemini Therapeutics?

Which has higher valuation and earnings, AMPH or GMTX?

Which has more volatility and risk, AMPH or GMTX?

Do analysts rate AMPH or GMTX?

Is AMPH or GMTX more profitable?

Does the media prefer AMPH or GMTX?

Do insiders & institutionals believe in AMPH or GMTX?

Summary

How does Amphastar Pharmaceuticals compare to IDEAYA Biosciences?

Do analysts prefer IDYA or AMPH?

Which has stronger earnings and valuation, IDYA or AMPH?

Do insiders and institutionals hold more shares of IDYA or AMPH?

Is IDYA or AMPH more profitable?

Which has more risk and volatility, IDYA or AMPH?

Does the media favor IDYA or AMPH?

Summary

How does Amphastar Pharmaceuticals compare to Beam Therapeutics?

Which has more risk & volatility, AMPH or BEAM?

Do institutionals and insiders believe in AMPH or BEAM?

Is AMPH or BEAM more profitable?

Do analysts rate AMPH or BEAM?

Which has stronger valuation & earnings, AMPH or BEAM?

Does the media prefer AMPH or BEAM?

Summary

How does Amphastar Pharmaceuticals compare to Ultragenyx Pharmaceutical?

Which has more risk & volatility, AMPH or RARE?

Which has stronger earnings & valuation, AMPH or RARE?

Do analysts recommend AMPH or RARE?

Is AMPH or RARE more profitable?

Does the media refer more to AMPH or RARE?

Do institutionals & insiders hold more shares of AMPH or RARE?

Summary

How does Amphastar Pharmaceuticals compare to Enliven Therapeutics?

Do analysts rate ELVN or AMPH?

Which has more risk & volatility, ELVN or AMPH?

Do institutionals and insiders have more ownership in ELVN or AMPH?

Which has preferable earnings and valuation, ELVN or AMPH?

Is ELVN or AMPH more profitable?

Does the media prefer ELVN or AMPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH vs. The Competition

Amphastar Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools